APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Industry Research

PD-1 and PD-L1 Inhibitor Industry Research Report 2026

29 December 2025125 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitor Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitor Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitor Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global PD-1 and PD-L1 Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for PD-1 and PD-L1 Inhibitor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for PD-1 and PD-L1 Inhibitor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of PD-1 and PD-L1 Inhibitor include Bristol Myers Squibb, Bristol-Myers Squibb, Regeneron Pharmaceuticals, AstraZeneca, Beigene, Hengrui Medicine, Pfizer, Junshi Biosciences and Akeso, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global PD-1 and PD-L1 Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

PD-1 and PD-L1 Inhibitor Market by Company

Bristol Myers Squibb

Bristol-Myers Squibb

Regeneron Pharmaceuticals

AstraZeneca

Beigene

Hengrui Medicine

Pfizer

Junshi Biosciences

Akeso

Alphamab Oncology

Roche

Merck

Sanofi

Innovent Biologics

PD-1 and PD-L1 Inhibitor Segment by Type

Monoclonal Antibody

Bispecific Antibody

PD-1 and PD-L1 Inhibitor Segment by Application

Lung Cancer

Breast Cancer

Stomach Cancer

Rectal Cancer

Others

PD-1 and PD-L1 Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of PD-1 and PD-L1 Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of PD-1 and PD-L1 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global PD-1 and PD-L1 Inhibitor Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global PD-1 and PD-L1 Inhibitor Sales (Tons) of Manufacturers (2021-2026) Table 7. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 8. Global PD-1 and PD-L1 Inhibitor Revenue of Manufacturers (2021-2026) Table 9. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers (2021-2026) Table 10. Global Market PD-1 and PD-L1 Inhibitor Average Price (US$/Ton) of Manufacturers (2021-2026) Table 11. Global PD-1 and PD-L1 Inhibitor Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of PD-1 and PD-L1 Inhibitor, Product Type & Application Table 14. Global PD-1 and PD-L1 Inhibitor Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global PD-1 and PD-L1 Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Bristol Myers Squibb Company Information Table 19. Bristol Myers Squibb Business Overview Table 20. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 21. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 22. Bristol Myers Squibb Recent Developments Table 23. Bristol-Myers Squibb Company Information Table 24. Bristol-Myers Squibb Business Overview Table 25. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 26. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 27. Bristol-Myers Squibb Recent Developments Table 28. Regeneron Pharmaceuticals Company Information Table 29. Regeneron Pharmaceuticals Business Overview Table 30. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 31. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio Table 32. Regeneron Pharmaceuticals Recent Developments Table 33. AstraZeneca Company Information Table 34. AstraZeneca Business Overview Table 35. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 36. AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio Table 37. AstraZeneca Recent Developments Table 38. Beigene Company Information Table 39. Beigene Business Overview Table 40. Beigene PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 41. Beigene PD-1 and PD-L1 Inhibitor Product Portfolio Table 42. Beigene Recent Developments Table 43. Hengrui Medicine Company Information Table 44. Hengrui Medicine Business Overview Table 45. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 46. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio Table 47. Hengrui Medicine Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 51. Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio Table 52. Pfizer Recent Developments Table 53. Junshi Biosciences Company Information Table 54. Junshi Biosciences Business Overview Table 55. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 56. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio Table 57. Junshi Biosciences Recent Developments Table 58. Akeso Company Information Table 59. Akeso Business Overview Table 60. Akeso PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 61. Akeso PD-1 and PD-L1 Inhibitor Product Portfolio Table 62. Akeso Recent Developments Table 63. Alphamab Oncology Company Information Table 64. Alphamab Oncology Business Overview Table 65. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 66. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio Table 67. Alphamab Oncology Recent Developments Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 71. Roche PD-1 and PD-L1 Inhibitor Product Portfolio Table 72. Roche Recent Developments Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 76. Merck PD-1 and PD-L1 Inhibitor Product Portfolio Table 77. Merck Recent Developments Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 81. Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio Table 82. Sanofi Recent Developments Table 83. Innovent Biologics Company Information Table 84. Innovent Biologics Business Overview Table 85. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 86. Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio Table 87. Innovent Biologics Recent Developments Table 88. Global PD-1 and PD-L1 Inhibitor Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2026) & (Tons) Table 90. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2021-2026) Table 91. Global PD-1 and PD-L1 Inhibitor Sales by Region (2027-2032) & (Tons) Table 92. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2027-2032) Table 93. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 94. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2021-2026) Table 95. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 96. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2027-2032) Table 97. North America PD-1 and PD-L1 Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 99. North America PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 100. North America PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 101. North America PD-1 and PD-L1 Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe PD-1 and PD-L1 Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 104. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 105. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 109. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 110. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 112. South America PD-1 and PD-L1 Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 114. South America PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 115. South America PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 116. South America PD-1 and PD-L1 Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 119. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 120. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2027-2032) & (US$ Million) Table 122. Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 123. Global PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 124. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2026) Table 125. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2027-2032) Table 126. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 127. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 128. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2026) Table 129. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2027-2032) Table 130. Global PD-1 and PD-L1 Inhibitor Price by Type (2021-2026) & (US$/Ton) Table 131. Global PD-1 and PD-L1 Inhibitor Price by Type (2027-2032) & (US$/Ton) Table 132. Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 133. Global PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 134. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2026) Table 135. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2027-2032) Table 136. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 137. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 138. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2026) Table 139. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2027-2032) Table 140. Global PD-1 and PD-L1 Inhibitor Price by Application (2021-2026) & (US$/Ton) Table 141. Global PD-1 and PD-L1 Inhibitor Price by Application (2027-2032) & (US$/Ton) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. PD-1 and PD-L1 Inhibitor Distributors List Table 145. PD-1 and PD-L1 Inhibitor Customers List Table 146. PD-1 and PD-L1 Inhibitor Industry Trends Table 147. PD-1 and PD-L1 Inhibitor Industry Drivers Table 148. PD-1 and PD-L1 Inhibitor Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. PD-1 and PD-L1 Inhibitor Product Image Figure 5. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global PD-1 and PD-L1 Inhibitor Market Size (2021-2032) & (US$ Million) Figure 7. Global PD-1 and PD-L1 Inhibitor Sales (2021-2032) & (Tons) Figure 8. Global PD-1 and PD-L1 Inhibitor Average Price (US$/Ton) & (2021-2032) Figure 9. Monoclonal Antibody Product Image Figure 10. Bispecific Antibody Product Image Figure 11. Lung Cancer Product Image Figure 12. Breast Cancer Product Image Figure 13. Stomach Cancer Product Image Figure 14. Rectal Cancer Product Image Figure 15. Others Product Image Figure 16. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 PD-1 and PD-L1 Inhibitor Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global PD-1 and PD-L1 Inhibitor Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global PD-1 and PD-L1 Inhibitor Sales by Region in 2025 Figure 22. Global PD-1 and PD-L1 Inhibitor Revenue by Region in 2025 Figure 23. North America PD-1 and PD-L1 Inhibitor Market Size by Country in 2025 Figure 24. North America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 25. North America PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2021-2032) Figure 26. United States PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe PD-1 and PD-L1 Inhibitor Market Size by Country in 2025 Figure 29. Europe PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 30. Europe PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2021-2032) Figure 31. Germany PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Asia Pacific PD-1 and PD-L1 Inhibitor Market Size by Country in 2025 Figure 37. Asia Pacific PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 38. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2021-2032) Figure 39. China PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Japan PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. South Korea PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. India PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Australia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. China Taiwan PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South America PD-1 and PD-L1 Inhibitor Market Size by Country in 2025 Figure 48. South America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 49. South America PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2021-2032) Figure 50. Mexico PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Brazil PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Argentina PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country in 2025 Figure 54. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2021-2032) Figure 56. Turkey PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2032) Figure 60. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2032) Figure 61. Global PD-1 and PD-L1 Inhibitor Price (US$/Ton) by Type (2021-2032) Figure 62. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2032) Figure 63. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2032) Figure 64. Global PD-1 and PD-L1 Inhibitor Price (US$/Ton) by Application (2021-2032) Figure 65. PD-1 and PD-L1 Inhibitor Value Chain Figure 66. PD-1 and PD-L1 Inhibitor Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges

Scope & coverage.

Types
  • Monoclonal Antibody
  • Bispecific Antibody
Applications
  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Rectal Cancer
  • Others
Companies covered
  • Bristol Myers Squibb
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals
  • AstraZeneca
  • Beigene
  • Hengrui Medicine
  • Pfizer
  • Junshi Biosciences
  • Akeso
  • Alphamab Oncology
  • Roche
  • Merck
  • Sanofi
  • Innovent Biologics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global PD-1 and PD-L1 Inhibitor Market Size (2021-2032)
  4. 2.2.2 Global PD-1 and PD-L1 Inhibitor Sales (2021-2032)
  5. 2.2.3 Global PD-1 and PD-L1 Inhibitor Market Average Price (2021-2032)
  6. 2.3 PD-1 and PD-L1 Inhibitor by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Monoclonal Antibody
  9. 2.3.3 Bispecific Antibody
  10. 2.4 PD-1 and PD-L1 Inhibitor by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Lung Cancer
  13. 2.4.3 Breast Cancer
  14. 2.4.4 Stomach Cancer
  15. 2.4.5 Rectal Cancer
  16. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global PD-1 and PD-L1 Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global PD-1 and PD-L1 Inhibitor Sales (Tons) of Manufacturers (2021-2026)
  3. 3.3 Global PD-1 and PD-L1 Inhibitor Revenue of Manufacturers (2021-2026)
  4. 3.4 Global PD-1 and PD-L1 Inhibitor Average Price by Manufacturers (2021-2026)
  5. 3.5 Global PD-1 and PD-L1 Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of PD-1 and PD-L1 Inhibitor, Product Type & Application
  8. 3.8 Global Manufacturers of PD-1 and PD-L1 Inhibitor, Established Date
  9. 3.9 Global PD-1 and PD-L1 Inhibitor Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Bristol Myers Squibb
  2. 4.1.1 Bristol Myers Squibb Company Information
  3. 4.1.2 Bristol Myers Squibb Business Overview
  4. 4.1.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  6. 4.1.5 Bristol Myers Squibb Recent Developments
  7. 4.2 Bristol-Myers Squibb
  8. 4.2.1 Bristol-Myers Squibb Company Information
  9. 4.2.2 Bristol-Myers Squibb Business Overview
  10. 4.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  12. 4.2.5 Bristol-Myers Squibb Recent Developments
  13. 4.3 Regeneron Pharmaceuticals
  14. 4.3.1 Regeneron Pharmaceuticals Company Information
  15. 4.3.2 Regeneron Pharmaceuticals Business Overview
  16. 4.3.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio
  18. 4.3.5 Regeneron Pharmaceuticals Recent Developments
  19. 4.4 AstraZeneca
  20. 4.4.1 AstraZeneca Company Information
  21. 4.4.2 AstraZeneca Business Overview
  22. 4.4.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio
  24. 4.4.5 AstraZeneca Recent Developments
  25. 4.5 Beigene
  26. 4.5.1 Beigene Company Information
  27. 4.5.2 Beigene Business Overview
  28. 4.5.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio
  30. 4.5.5 Beigene Recent Developments
  31. 4.6 Hengrui Medicine
  32. 4.6.1 Hengrui Medicine Company Information
  33. 4.6.2 Hengrui Medicine Business Overview
  34. 4.6.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio
  36. 4.6.5 Hengrui Medicine Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 Junshi Biosciences
  44. 4.8.1 Junshi Biosciences Company Information
  45. 4.8.2 Junshi Biosciences Business Overview
  46. 4.8.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio
  48. 4.8.5 Junshi Biosciences Recent Developments
  49. 4.9 Akeso
  50. 4.9.1 Akeso Company Information
  51. 4.9.2 Akeso Business Overview
  52. 4.9.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio
  54. 4.9.5 Akeso Recent Developments
  55. 4.10 Alphamab Oncology
  56. 4.10.1 Alphamab Oncology Company Information
  57. 4.10.2 Alphamab Oncology Business Overview
  58. 4.10.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio
  60. 4.10.5 Alphamab Oncology Recent Developments
  61. 4.11 Roche
  62. 4.11.1 Roche Company Information
  63. 4.11.2 Roche Business Overview
  64. 4.11.3 Roche PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio
  66. 4.11.5 Roche Recent Developments
  67. 4.12 Merck
  68. 4.12.1 Merck Company Information
  69. 4.12.2 Merck Business Overview
  70. 4.12.3 Merck PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio
  72. 4.12.5 Merck Recent Developments
  73. 4.13 Sanofi
  74. 4.13.1 Sanofi Company Information
  75. 4.13.2 Sanofi Business Overview
  76. 4.13.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio
  78. 4.13.5 Sanofi Recent Developments
  79. 4.14 Innovent Biologics
  80. 4.14.1 Innovent Biologics Company Information
  81. 4.14.2 Innovent Biologics Business Overview
  82. 4.14.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio
  84. 4.14.5 Innovent Biologics Recent Developments
5 Global PD-1 and PD-L1 Inhibitor Market Scenario by Region
  1. 5.1 Global PD-1 and PD-L1 Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021-2032
  3. 5.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021-2026
  4. 5.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2027-2032
  5. 5.3 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2021-2032
  6. 5.3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2021-2026
  7. 5.3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2027-2032
  8. 5.4 North America PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
  9. 5.4.1 North America PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  11. 5.4.3 North America PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
  15. 5.5.1 Europe PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  17. 5.5.3 Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
  35. 5.7.1 South America PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  37. 5.7.3 South America PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032)
  2. 6.1.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032) & (Tons)
  3. 6.1.2 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2032)
  4. 6.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2032)
  5. 6.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2032)
  7. 6.3 Global PD-1 and PD-L1 Inhibitor Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032)
  2. 7.1.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032) & (Tons)
  3. 7.1.2 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2032)
  4. 7.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2032)
  5. 7.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2032)
  7. 7.3 Global PD-1 and PD-L1 Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 PD-1 and PD-L1 Inhibitor Value Chain Analysis
  2. 8.1.1 PD-1 and PD-L1 Inhibitor Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 PD-1 and PD-L1 Inhibitor Production Mode & Process
  5. 8.2 PD-1 and PD-L1 Inhibitor Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 PD-1 and PD-L1 Inhibitor Distributors
  8. 8.2.3 PD-1 and PD-L1 Inhibitor Customers
9 Global PD-1 and PD-L1 Inhibitor Analyzing Market Dynamics
  1. 9.1 PD-1 and PD-L1 Inhibitor Industry Trends
  2. 9.2 PD-1 and PD-L1 Inhibitor Industry Drivers
  3. 9.3 PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges
  4. 9.4 PD-1 and PD-L1 Inhibitor Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst